Jim Brown Sells 5,000 Shares of USANA Health Sciences, Inc. (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) CEO Jim Brown sold 5,000 shares of USANA Health Sciences stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $29.47, for a total transaction of $147,350.00. Following the sale, the chief executive officer now owns 15,716 shares in the company, valued at approximately $463,150.52. This represents a 24.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

USANA Health Sciences Stock Down 0.9 %

Shares of NYSE USNA opened at $29.72 on Wednesday. The firm’s 50-day simple moving average is $33.34 and its 200 day simple moving average is $36.41. The stock has a market cap of $566.44 million, a P/E ratio of 10.50, a P/E/G ratio of 0.93 and a beta of 0.87. USANA Health Sciences, Inc. has a fifty-two week low of $27.71 and a fifty-two week high of $50.32.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. The firm had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. On average, sell-side analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Sidoti cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. DA Davidson cut their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th. Finally, StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Martingale Asset Management L P grew its holdings in USANA Health Sciences by 2.1% during the third quarter. Martingale Asset Management L P now owns 16,732 shares of the company’s stock worth $634,000 after acquiring an additional 340 shares during the period. KBC Group NV grew its holdings in USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after acquiring an additional 519 shares during the period. R Squared Ltd acquired a new position in USANA Health Sciences during the fourth quarter worth about $28,000. Safe Harbor Fiduciary LLC purchased a new position in USANA Health Sciences in the 3rd quarter worth about $30,000. Finally, Exchange Traded Concepts LLC increased its stake in USANA Health Sciences by 11.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,578 shares of the company’s stock worth $308,000 after purchasing an additional 869 shares in the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.